Thymosin Alpha-1 Plus Interferon Improves Hepatitis C Treatment in a Randomized Trial
Adding thymosin alpha-1 to interferon-alpha doubled the sustained virological response rate (40% vs 20%) in naive hepatitis C patients compared to interferon alone in this randomized pilot study.
Quick Facts
What This Study Found
Thymosin alpha-1 + interferon-alpha achieved 40% SVR versus 20% for interferon alone in naive chronic hepatitis C patients (n=22), demonstrating significant immune-mediated enhancement of antiviral efficacy.
Key Numbers
How They Did This
Randomized controlled pilot study. 22 naive chronic HCV patients randomized to IFN-alpha + thymosin alpha-1 (n=11) or IFN-alpha alone (n=11). SVR (sustained virological response) as primary endpoint.
Why This Research Matters
Before direct-acting antivirals, hepatitis C treatment relied on interferon with limited success. Thymosin alpha-1 doubled the cure rate — a clinically meaningful improvement through immune enhancement.
The Bigger Picture
While DAAs have revolutionized HCV treatment, this study demonstrates thymosin alpha-1's ability to enhance antiviral immunity — a principle applicable to other viral infections without direct antiviral drugs.
What This Study Doesn't Tell Us
Small pilot study (n=22). Not powered for statistical significance. Pre-DAA era; clinical context has changed. Open-label design potential bias.
Questions This Raises
- ?Could thymosin alpha-1 enhance DAA therapy for difficult-to-treat HCV genotypes?
- ?Is the immune-enhancing principle applicable to other viral infections?
- ?What is the optimal duration of combination thymosin alpha-1 + antiviral therapy?
Trust & Context
- Key Stat:
- Cure rate doubled SVR went from 20% (IFN alone) to 40% (IFN + thymosin alpha-1) — doubling the hepatitis C cure rate through immune enhancement
- Evidence Grade:
- Moderate evidence from a randomized pilot study with clinically relevant SVR endpoint, limited by small sample size.
- Study Age:
- Published in 2004. HCV treatment has been revolutionized by DAAs, but thymosin alpha-1's immune-enhancing principle remains relevant for other infections.
- Original Title:
- Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.
- Published In:
- Journal of viral hepatitis, 11(1), 69-73 (2004)
- Authors:
- Andreone, P(2), Gramenzi, A(2), Cursaro, C(2), Felline, F, Loggi, E, D'Errico, A, Spinosa, M, Lorenzini, S, Biselli, M, Bernardi, M
- Database ID:
- RPEP-00880
Evidence Hierarchy
Frequently Asked Questions
Can thymosin alpha-1 cure hepatitis C?
In this study, adding it to interferon doubled the cure rate from 20% to 40%. While newer drugs (DAAs) have since transformed HCV treatment, this demonstrates thymosin alpha-1's powerful immune-enhancing ability.
Is this relevant now that better HCV drugs exist?
The specific HCV application is less relevant with DAAs available. But the principle — that thymosin alpha-1 can meaningfully enhance antiviral immunity — applies to other infections where direct antivirals don't exist or aren't sufficient.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00880APA
Andreone, P; Gramenzi, A; Cursaro, C; Felline, F; Loggi, E; D'Errico, A; Spinosa, M; Lorenzini, S; Biselli, M; Bernardi, M. (2004). Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.. Journal of viral hepatitis, 11(1), 69-73.
MLA
Andreone, P, et al. "Thymosin-alpha 1 plus interferon-alpha for naive patients with chronic hepatitis C: results of a randomized controlled pilot trial.." Journal of viral hepatitis, 2004.
RethinkPeptides
RethinkPeptides Research Database. "Thymosin-alpha 1 plus interferon-alpha for naive patients wi..." RPEP-00880. Retrieved from https://rethinkpeptides.com/research/andreone-2004-thymosinalpha-1-plus-interferonalpha
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.